Ordering peptides from overseas: what the import rules say

The starting position is a prohibition

The federal drug agency states its own baseline in plain words. In most circumstances, it is illegal for individuals to import drugs or devices into the United States for personal use.

The reason it gives is that such products often have not been approved for use and sale here. It adds the case people most often assume is the exception: if a drug is approved in another country but is an unapproved new drug in the United States, it is illegal to import.

That matters directly in this market, because most peptide compounds are not FDA-approved drugs in the United States regardless of what any other country has done with them.

The statute behind that is short as well. Articles that appear adulterated, misbranded or in violation of the drug approval provisions shall be refused admission, and an article that appears to be a counterfeit drug shall be refused admission.

What the personal importation policy actually is

The often-cited allowance is not a right, an exemption or a quantity permission. It is a set of factors agency staff may weigh when deciding what to do with a parcel.

The agency's own procedures manual says so directly. Although the agency may use discretion to allow admission of certain violative items, this should not be interpreted as a license to individuals to bring in such shipments.

Read that sentence twice, because it is the whole of the misunderstanding. Discretion exercised in some cases is not permission in any case.

The manual frames the policy as a resource decision as much as anything else. Personal shipments are normally small in size and value, comprehensive coverage of them is not normally justified, and the procedures exist to protect consumers with a reasonable expenditure of resources.

The two situations where a more permissive decision may be considered

The manual sets out two, and both are narrower than the folklore version.

The first is where the intended use is appropriately identified, that use is not for treatment of a serious condition, and the product is not known to represent a significant health risk.

The second applies to a serious condition, and it carries four conditions at once. The intended use must be unapproved and for a serious condition for which effective treatment may not be available domestically. There must be no known commercialization or promotion to persons residing in the United States by those distributing the product. The product must not represent an unreasonable risk. And the individual must affirm in writing that it is for their own use, generally not more than a three-month supply. That affirmation must also either name a United States licensed doctor responsible for their treatment, or show the product continues treatment begun abroad.

The three-month figure people quote lives inside that second situation, attached to the other three conditions. It was never a standalone allowance.

The condition that most overseas peptide sellers fail on sight

One clause does most of the work, and it is the one least often quoted.

The manual requires that there be no known commercialization or promotion of the product to persons residing in the United States by those involved in its distribution.

A website that advertises to an American audience, prices in dollars, offers domestic shipping options and answers customer questions in English is promotion to persons residing in the United States. It does not clear that condition; it is the thing the condition describes.

The manual is blunter still one page earlier. Commercial and promotional shipments are not subject to these procedures at all. Whether a shipment is commercial may be judged from the type of product, accompanying literature, size, value and destination, and from whether the quantity suggests commercial distribution rather than personal use.

So the ordinary case of ordering from an overseas storefront is not the case the personal importation policy is about. The policy is written around travelers, personal representatives, and shipments from a foreign facility where someone was treated.

What happens to a parcel in practice

Mail is handled jointly, and the sequence is documented.

Customs officers examine parcels arriving through international mail facilities. They set aside anything that appears to contain a drug, biologic or device, anything the drug agency has asked to be held, and anything that looks like health fraud or an unknown risk to health.

Agency staff then audit those parcels. Usually a documentary sample is enough, meaning the labeling and inserts rather than the contents. Detained parcels stay in customs custody until they are released or refused entry.

Where a drug is refused admission, disposition is a customs responsibility, except that lower-value refused drugs are destroyed by the drug agency itself.

There is also a middle outcome. Staff may release a shipment with comment, and advise the recipient of three things. That the product appears unapproved in the United States. That it should be used under medical supervision. And that future shipments of it may be detained.

A parcel that arrived once is not a ruling that the next one will.

The four grounds for refusal, and the counterfeit overlap

The agency publishes when it would refuse a personal importation, and the list is short.

When the product is on an import alert for previous violations. When the shipment appears intended for commercial distribution. When the product appears to present a serious risk to health. And when the article appears to represent health fraud.

The second of those is the one an ordinary consumer order collides with, for the reasons above.

There is also a supply-chain reason the agency watches inbound mail closely. Its own counterfeit guidance states that many counterfeit drugs are made abroad and arrive in the United States through the mail or are smuggled in.

That is a separate risk from the legal one, and it does not go away because a parcel was delivered.

Two adjacent rules worth not confusing

Controlled substances are handled by a different agency. Where a medication is also a controlled substance, the drug enforcement agency generally decides whether it may be imported for personal use, and the two agencies coordinate where both have jurisdiction.

Foreign nationals visiting the United States are treated under a different paragraph, which allows bringing or shipping a ninety-day supply of drug products, with documentation suggested for mailed medication.

Neither of those is the rule that applies to a United States resident ordering from an overseas seller, and both are routinely quoted as if they were.

A reader's own situation is a question for a lawyer or the agencies themselves. What is published, and what is set out above, is the framework rather than the answer.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Personal Importation, Import Basics — U.S. Food and Drug Administration, August 2025
2. Regulatory Procedures Manual, Chapter 9: Import Operations and Actions, section 9-2 Coverage of Personal Importations — U.S. Food and Drug Administration, March 2024
3. United States Code Title 21, Section 381(a), Imports and exports, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
4. Counterfeit Medicine — U.S. Food and Drug Administration, December 2025